Canadà - anglès - Health Canada

sandoz canada incorporated - prochlorperazine (prochlorperazine mesylate) - liquid - 5mg - prochlorperazine (prochlorperazine mesylate) 5mg - phenothiazines

Uganda - anglès - National Drug Authority

bremer pharma gmbh - piperazine citrate - oral liquid ordinary soluble powders - 100gm

Estats Units - anglès - NLM (National Library of Medicine)

walgreens co - piperazine citrate (unii: 63kp7fxf2i) (piperazine - unii:1rtm4pal0v) - piperazine 275 mg in 4.93 ml - uses: ■ a liquid dog and cat wormer for use in food or drinking water for the removal of large roundworms (ascarids) (toxocara canis, toxocara cati, toxascaris leonina).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - caffeine, quantity: 12.5 mg - oral liquid, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; water for injections - cafnea oral solution is indicated for the short-term treatment of apnoea of prematurity in infants between 28 and 33 weeks gestational age.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - posaconazole, quantity: 40 mg/ml - suspension - excipient ingredients: sodium benzoate; liquid glucose; titanium dioxide; polysorbate 80; xanthan gum; purified water; sodium citrate dihydrate; glycerol; simethicone; citric acid monohydrate; flavour - noxafil (posaconazole) is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older; invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy; fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. noxafil is also indicated for the: treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole.prophylaxis of invasive fungal infections, among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - trifluoperazine hydrochloride - oral tablet - 5mg

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: tartaric acid; hydrochloric acid; benzoic acid; purified water - risperidone bnm is indicated for the treatment of schizophrenia and related psychoses.,risperidone bnm is indicated for the short-term treatment of acute mania associated with bipolar 1 disorder.,risperidone bnm is indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,risperidone bnm is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,risperidone bnm is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - lacosamide, quantity: 10 mg - solution - excipient ingredients: glycerol; sodium chloride; carmellose sodium; sorbitol solution (70 per cent) (crystallising); macrogol 4000; citric acid; acesulfame potassium; sodium methyl hydroxybenzoate; purified water; flavour - vimpat (lacosamide) tablets and oral solution are indicated as:,? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.,? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older.,? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Estats Units - anglès - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 5 mg - prochlorperazine maleate tablets are indicated for the control of severe nausea and vomiting. prochlorperazine maleate tablets are also indicated for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine maleate is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. this evide

Estats Units - anglès - NLM (National Library of Medicine)

akorn - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide 500 mg - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.*4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendation of cdc. it is possible these patients may require a longer course of treatment). it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease control